Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Approves Breakthrough Cancer Therapy Provenge

April 30, 2010 10:30 am | by Matthew Perrone, AP Business Writer | News | Comments

Dendreon Corp.'s Provenge, a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.


Simulation Software

April 30, 2010 7:08 am | Product Releases | Comments

The time-consuming scientific research behind drug discovery can now be accelerated with the launch of AMBER 11, a software tool that enables bio-scientists to harness the power of supercomputing on their desktop PC.


Biomarker Panel

April 30, 2010 6:46 am | Product Releases | Comments

Beckman Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel of conjugated-antibody cocktails for the characterization of hematolymphoid neoplasia by flow cytometry.


Commentary: Will Provenge Be New Standard of Care?

April 30, 2010 6:36 am | by Fleur Pijpers, Senior Analyst, Datamonitor | News | Comments

Despite FDA approval, it remains to be seen how frequently Provenge will be used in castration-resistant prostate cancer (CRPC), according to a Datamonitor analyst.


CEVEC and Aragen Sign Strategic License Agreement

April 30, 2010 6:29 am | News | Comments

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California-based contract research and development organization, have signed of a strategic license agreement.


Mallinckrodt Baker Signs Deal With VWR International

April 30, 2010 6:17 am | News | Comments

Covidien announced that its Mallinckrodt Baker business unit has entered into a multi-year agreement with global laboratory supply company, VWR International, LLC, to distribute Mallinckrodt Baker’s J.T.Baker brand products in Eastern and Central Europe.


All Immunosuppressive Drugs Carry Same Cancer Risk

April 30, 2010 6:11 am | News | Comments

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).


University Finds MS Biomarkers A Decade Before Symptoms

April 30, 2010 6:07 am | News | Comments

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled.


FDA Approves Once-Daily Kaletra

April 30, 2010 5:56 am | News | Comments

Abbott announced that the U.S. Food and Drug Administration approved once-daily dosing of Kaletra for adult patients with HIV who have previously taken antiretroviral therapy.


Provenge Vaccine Receives FDA Approval

April 30, 2010 5:45 am | by Matthew Perrone | News | Comments

A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.


Schwarz Pharma to Pay $22M Over False Claims

April 30, 2010 5:43 am | News | Comments

The Justice Department says Schwarz Pharma Inc. will pay $22 million for allegedly failing to disclose that two of its products did not qualify for federal health care coverage.


United Therapeutics' Profits Jump 43% in Q1

April 30, 2010 5:40 am | News | Comments

United Therapeutics Corp.'s first-quarter profit increased 43 percent after the Food and Drug Administration approved two of its blood pressure drugs.


BMS Profits Up 16.5% for the Quarter

April 30, 2010 5:36 am | by Linda A. Johnson | News | Comments

Drugmaker Bristol-Myers Squibb Co. reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel due to the impact of the health care overhaul.


J & J Subsidiaries Settle Topamax Case

April 30, 2010 5:33 am | by Pete Yost | News | Comments

Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced.


Drugmakers Post Higher 1st-Quarter Profits

April 30, 2010 5:30 am | by Linda A. Johnson | News | Comments

Three top drugmakers have posted healthy increases in first-quarter sales and profits, with strong sales of key drugs buoying Bristol-Myers Squibb Co., AstraZeneca LP and Sanofi-Aventis SA.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.